Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is Bristol-Myers Squibb Company (BMY) Halal?

FAIL

Bristol-Myers Squibb Company · NYSE: BMY · Healthcare

The short answer

No — Bristol-Myers Squibb (BMY) fails this Shariah stock screen at the debt gate. The Princeton, New Jersey biopharma's business is fine: cardiovascular, oncology, immunology and hematology prescription medicines (Eliquis, Opdivo, Yervoy, Orencia, Revlimid, Camzyos) with no haram segments disclosed in its filings. But the balance sheet carries heavy interest-bearing debt — short-term $1,027M plus long-term $42,093M = $43,120M at June 30, 2026, largely from its acquisition history (including the $74B Celgene deal) — which is 33.38% of its ~$129.2B market cap (Finnhub, October 2026), above the ~33% ceiling. Interest income of $300M (Zoya's FY2025 figure) is only 0.62% of $48,194M revenue, under the 5% ceiling — that gate passes. Zoya flags BMY not Shariah-compliant (September 2026), and ShariaPortfolio rates it not compliant on financial ratios. A fail at any gate is an overall FAIL. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

Bristol-Myers Squibb Company (NYSE: BMY), founded in 1887 and headquartered in Princeton, New Jersey, is a global biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes and sells prescription medicines for serious diseases. Growth portfolio: cardiovascular Eliquis (apixaban — $4,481M of Q2 2026 revenue, up 22%) and Camzyos; oncology Opdivo/Opdivo Qvantig (nivolumab), Yervoy (ipilimumab) and Opdualag; immunology Orencia, Zeposia and Sotyktu; hematology Reblozyl and Abecma; neuroscience Cobenfy (xanomeline/trospium chloride). Legacy portfolio includes Revlimid (in steep generic decline — $425M in Q2 2026, down 49%) and Pomalyst. FY2025 total revenue of $48,194M = net product sales $46,756M + alliance and other revenues $1,438M (Form 10-K, fiscal year ended December 31, 2025, filed February 11, 2026; SEC CIK 0000014272). Business-screen implication (factual): all activity is pharmaceuticals/healthcare; the filings disclose no alcohol, gambling, conventional finance, pork, weapons or tobacco revenue — no haram segments. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: FAIL

Bristol-Myers Squibb's Form 10-Q for the quarter ended June 30, 2026 (SEC CIK 0000014272) reports short-term debt obligations of $1,027M and long-term debt of $42,093M — total interest-bearing debt of $43,120M (about $43.1B), confirmed by the net-debt table in BMY's Q2 2026 results release (cash $8,722M, marketable debt securities $2,742M). Against a market cap of about $129.2B (Finnhub, October 2026), debt ÷ market cap is 33.38% — above the ~33% ceiling. The debt load, built through BMY's acquisition history including the $74B Celgene acquisition, has been declining (about $45.1B at December 31, 2025), but it still sits above the ceiling. Cash, cash equivalents and marketable debt securities of $11,464M are about 8.87% of market cap, also below 33%, but a fail at the debt ratio alone is decisive. The debt gate fails. Facts only.

Gate 3 — Non-compliant income: PASS

BMY's Form 10-K for the fiscal year ended December 31, 2025 (filed February 11, 2026) reports total revenues of $48,194M. Zoya's BMY stock page cites FY2025 interest income of $300M — about 0.62% of revenue, below the 5% non-compliant income ceiling. The income gate passes. Facts only.

Key figures used

Frequently asked questions

What does Bristol-Myers Squibb do?

Bristol-Myers Squibb Company, founded in 1887 and headquartered in Princeton, New Jersey, is a global biopharmaceutical company that discovers, develops and commercialises prescription medicines for serious diseases. Key products: cardiovascular Eliquis (apixaban, $4,481M revenue in Q2 2026 alone) and Camzyos; oncology Opdivo/Opdivo Qvantig (nivolumab), Yervoy (ipilimumab) and Opdualag; immunology Orencia, Zeposia and Sotyktu; hematology Revlimid (in generic decline), Reblozyl and Abecma; and neuroscience Cobenfy. FY2025 total revenue was $48,194M ($46,756M net product sales + $1,438M alliance and other revenues). All pharmaceutical activity — the filings disclose no alcohol, gambling, conventional finance, pork, weapons or tobacco revenue.

Why does BMY fail this Shariah stock screen?

BMY fails this Shariah stock screen at the debt gate. Gate 1 (business activities): prescription biopharmaceuticals are healthcare activity — no haram segments disclosed, so it passes. Gate 2 (debt): the Q2 2026 balance sheet lists short-term debt obligations of $1,027M and long-term debt of $42,093M, a total of $43,120M, which is 33.38% of the ~$129.2B market cap (Finnhub, October 2026) — above the ~33% ceiling, so it fails. Gate 3 (interest income): Zoya cites FY2025 interest income of $300M, about 0.62% of $48,194M revenue — under the 5% ceiling, so it passes. A fail at any single gate is an overall FAIL. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

What is BMY's interest-bearing debt ratio?

Bristol-Myers Squibb's Form 10-Q for the quarter ended June 30, 2026 (SEC CIK 0000014272) reports short-term debt obligations of $1,027M and long-term debt of $42,093M — total interest-bearing debt of $43,120M (about $43.1B). The company's own Q2 2026 results present the same figures in its net-debt table (cash $8,722M against $1,027M short-term and $42,093M long-term debt). Against a market cap of about $129.2B (Finnhub, October 2026), debt ÷ market cap is 33.38% — above the ~33% ceiling. The debt, largely from BMY's acquisition history (including the $74B Celgene deal), has been declining (about $45.1B at year-end 2025), but it still sits above the ceiling. The debt gate fails.

What is BMY's non-compliant income ratio?

Bristol-Myers Squibb's Form 10-K for the fiscal year ended December 31, 2025 (filed February 11, 2026; SEC CIK 0000014272) reports total revenues of $48,194M ($46,756M net product sales + $1,438M alliance and other revenues). Zoya's BMY stock page cites FY2025 interest income of $300M — about 0.62% of $48,194M revenue, below the 5% non-compliant income ceiling. BMY's Q2 2026 net-debt disclosure separately shows cash, cash equivalents and marketable debt securities of $11,464M, about 8.87% of the ~$129.2B market cap — also below 33%. The income gate passes.

Do Zoya, Musaffa, or ShariaPortfolio cover BMY?

Zoya covers BMY (zoya.finance/stocks/bmy) and flags the stock not Shariah-compliant as of September 2026, though its public page renders contradictory auto-generated text (halal and not halal in the same FAQ block) and inconsistent interest-income figures across crawls — reported here as flagged-not-compliant by Zoya, not as a clean standalone rating. ShariaPortfolio covers BMY and rates it not Shariah Compliant because it fails the financial ratios. Musaffa: no BMY page was found via public search — no coverage found. All honestly reported as found, not invented. This page applies the screen directly from BMY's own SEC filings.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).